New Hope for Hypertension: Lorundrostat Data Signals Breakthrough

RADNOR, PA – May 18, 2026 – In the relentless battle against two of the world's most prevalent and deadly chronic conditions—uncontrolled hypertension and chronic kidney disease (CKD)—a new therapeutic candidate is poised for a major reveal. Mineralys Therapeutics has announced it will present new, detailed data from its pivotal Phase 3 Launch-HTN trial for lorundrostat at the upcoming 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) in Gdańsk, Poland.

The oral presentation, scheduled for May 30, is expected to provide a crucial look at the efficacy and safety of lorundrostat, a novel aldosterone synthase inhibitor, in a particularly vulnerable patient population: those whose high blood pressure remains dangerously elevated despite treatment with multiple existing medications and who also suffer from chronic kidney disease. This announcement comes as the company's New Drug Application (NDA) for lorundrostat is already under review by the U.S. Food and Drug Administration (FDA), setting the stage for a potentially transformative year for both Mineralys and the millions of patients seeking better treatment options.

Targeting the Hormonal Culprit

For decades, the medical community has recognized the intricate and destructive link between hypertension and CKD. High blood pressure can damage the delicate blood vessels in the kidneys, impairing their function, while failing kidneys are less able to regulate blood pressure, creating a vicious cycle. Emerging evidence has increasingly pointed to a key hormonal driver behind this damage: dysregulated aldosterone.

Produced by the adrenal glands, aldosterone plays a critical role in managing the body's salt and water balance. However, when produced in excess, it promotes sodium retention, vascular inflammation, and fibrosis, contributing directly to uncontrolled blood pressure and progressive kidney injury. Lorundrostat represents a new class of drugs known as aldosterone synthase inhibitors (ASIs), which are designed to tackle the problem at its source. Unlike older mineralocorticoid receptor antagonists (MRAs) like spironolactone, which block the receptors where aldosterone acts, lorundrostat is engineered to inhibit CYP11B2, the specific enzyme responsible for producing aldosterone.

This targeted approach is believed to offer a more complete suppression of aldosterone's harmful effects while potentially reducing the risk of side effects like hyperkalemia (high potassium levels), a significant concern that often limits the use of older MRAs, especially in patients with CKD. With a high selectivity for the aldosterone-producing enzyme—374 times greater than for the cortisol-producing enzyme—lorundrostat aims to provide a powerful and precise tool for physicians.

Pivotal Data on the Horizon

The upcoming presentation at ESH 2026 will be delivered by Dr. Liffert Vogt, a respected professor of Nephrology and Renal Transplantation from Amsterdam UMC. The focus will be on results from the global, randomized, and double-blind Launch-HTN trial. The study enrolled adults whose blood pressure remained uncontrolled even while taking between two and five different antihypertensive drugs—a group representing a significant unmet medical need.

Participants were randomized to receive either a placebo, a 50 mg daily dose of lorundrostat, or a 50 mg dose that could be increased to 100 mg. The trial's primary measure of success was the change in systolic blood pressure at six weeks compared to the placebo group. The data from the CKD patient subgroup is particularly anticipated, as this population is notoriously difficult to treat and at an exceptionally high risk for cardiovascular events like heart attacks and strokes.

"The development of a potent and selective ASI that can be safely used in patients with CKD would be a major step forward," commented one leading nephrologist not involved with the study. "We desperately need new therapies that can break the cardiorenal cycle without introducing prohibitive risks, and targeting aldosterone synthesis is one of the most promising strategies we've seen in years."

Navigating a Crowded but Needy Market

Should the data prove positive and regulatory approval follow, lorundrostat will enter a complex and competitive market. The current standard of care for hypertension and CKD includes well-established drug classes like ACE inhibitors and ARBs. More recently, SGLT2 inhibitors and the non-steroidal MRA finerenone have become mainstays for protecting the kidneys, particularly in patients with diabetes.

However, a substantial portion of patients—up to 40% of those with CKD—still suffer from resistant hypertension. It is this gap that Mineralys aims to fill. Lorundrostat is not alone in this pursuit. Other ASIs, such as baxdrostat from CinCor Pharma (now part of AstraZeneca) and Boehringer Ingelheim's vicadrostat, are also in late-stage development, signaling a broader industry shift towards targeting aldosterone synthesis. Analysts believe the market is large enough to support multiple new entrants, given the sheer scale of the patient population.

The success of lorundrostat will depend not only on its efficacy in lowering blood pressure but also on its safety profile, particularly concerning potassium levels, and its ability to demonstrate long-term benefits in slowing kidney disease progression. While an earlier trial in patients with obstructive sleep apnea (OSA) did not meet its primary endpoint, the drug's consistent and robust blood pressure-lowering effects across multiple studies have kept investor and clinician interest high.

The Path to Market and Public Health Impact

The journey from clinical trial to pharmacy shelf is already well underway. The FDA accepted Mineralys's NDA for lorundrostat late last year and has set a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. This formal review milestone has buoyed investor confidence, with many financial analysts maintaining a "Strong Buy" rating on Mineralys stock (Nasdaq: MLYS) and setting price targets that suggest significant upside.

The company appears well-capitalized for a potential product launch, reporting a cash position of over $640 million at the end of the last quarter, allowing it to ramp up pre-commercial activities. The potential public health impact of an effective new treatment cannot be overstated. In the United States alone, hypertension is a contributing cause in nearly 700,000 deaths annually and carries an economic burden exceeding $200 billion. By providing a new mechanism to control blood pressure in the most difficult-to-treat patients, lorundrostat could help reduce the incidence of stroke, heart failure, and end-stage kidney disease requiring dialysis or transplantation.

As the medical community awaits the full data from Gdańsk, the presentation represents more than just a corporate milestone for Mineralys Therapeutics. It marks a potential turning point for millions of patients, offering a glimmer of hope that a more effective weapon against these interconnected silent killers is finally within reach. The results shared at ESH 2026 will be a critical indicator of whether lorundrostat can fulfill its promise and redefine the standard of care for a population in desperate need of a breakthrough.